Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalised community-acquired pneumonia patients - Intravenous followed by oral therapy

Clinical Drug Investigation

Volumn 14, Issue 6, 1997, Pages 439-449

  Vetter, N ^a   Stamler, D ^b   O'Neill, S ^c   Rafferty, P ^d   Praz, G ^e   Duran Cantolla, J ^f   Pongratz Roger, M ^g   Aigner, K ^h   Bolitschek, J ^h   Garcia Puig, J ⁱ   Afilalo, M ^j   Small, D ^j   Winter, J ^k  

^a Pulmologisches Zentrum   (Austria)

^b ABBOTT LABORATORIES   (United States)

^c BEAUMONT HOSPITAL   (Ireland)

^d DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

^e Institut Central des Hopitaux Valaisans   (Switzerland)

^f HOSPITAL TXAGORRITXU   (Spain)

^g GENERAL HOSPITAL KLAGENFURT   (Austria)

^h ELISABETHINEN HOSPITAL   (Austria)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j MCGILL UNIVERSITY   (Canada)

^k King's Cross Hospital   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN;

ABDOMINAL PAIN; ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; THROMBOPHLEBITIS; VOMITING;

EID: 6844249445     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714060-00001     Document Type: Article

References (18)

1. Woodhead MA, MacFarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1: 671-4
2. British Thoracic Society Research Committee and Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987; 62: 195-220
3. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11: 586-99
4. American Thoracic Society Consensus Committee. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26
5. Slack R, McCabe M, Bucknall, CE, et al. Audit of hospital management of pneumonia. Thorax 1992; 47: 461-2
6. Kerttula Y, Leinonen M, Koskela M, et al. The aetiology of pneumonia. Application of bacterial serology and basic laboratory methods. J Infect 1987; 14: 21-30
7. Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69: 307-16.
8. Blanquer J, Blanquer R, Borras R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991; 46: 508-11
9. Jones RN, Doern G, Gerlach EH, et al. Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. Diagn Microbiol Infect Dis 1994; 18: 243-9
10. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 1710
11. Hardy DJ, Swanson RN, Rode RA, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990; 34: 1407-13
12. Hardy DJ, Guay DRP, Jones RN. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological and clinical overview. Diagn Microbiol Infect Dis 1992; 15: 39-53
13. Anderson G, Esmonde TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991; 27 Suppl. A: 117-24
14. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50
15. CPMP Working Party on Efficacy of Medicinal Products. EEC note for guidance: good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol 1990; 67: 361-72
16. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, et al. The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991; 85: 313-7
17. Guay DRP, Siepman N, Tanaka SK, et al. Comparative safety and efficacy of clarithromycin and 3 oral cephalosporins in the treatment of outpatients with bacterial bronchitis due to Haemophilus influenzae. Drug Invest 1993; 6: 33-41
18. Guay DRP, Patterson DR, Siepman N, et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993; 8: 350-64